Literature DB >> 6111576

Circulating immune complexes, immunoconglutinins, and rheumatoid factors in nephropathia epidemica.

K Penttinen, J Lähdevirta, R Kekomäki, B Ziola, A Salmi, A Hautanen, P Lindström, A Vaheri, M Brummer-Korvenkontio, O Wager.   

Abstract

Circulating immune complexes (CICs), immunoconglutinins, and antiglobulins were studied in nephropathia epidemica, an acute infectious hemorrhagic fever occurring in Finland and Scandinavia. Sixty-one serum specimens from 18 serologically confirmed patients were collected between day -5 and day 230 from the onset of fever. Five CIC tests, three immunoconglutinin tests, and various other tests were used to characterize the disease immunologically. CICs were found in all patients. The percentage detection of positive cases varied in the tests from 100% to 22%. A marked stimulation of levels of the IgM class of immunoglobulins were observed. Antiglobulin tests were positive for all of the patients. No correlation between the test results and the clinical severity of the disease could be found. Of special interest was the delay in the rise of CIC levels compared with the chromologic pattern of the clinical course. In some patients a prolonged appearance of CICs for eight months was observed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6111576     DOI: 10.1093/infdis/143.1.15

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Detection of nephropathia epidemica (Puumala virus)-specific immunoglobulin M by enzyme-linked immunosorbent assay.

Authors:  B Niklasson; T Kjelsson
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

2.  Anti-endothelial cell antibodies in nephropathia epidemica and other viral diseases.

Authors:  A G Wangel; M Temonen; M Brummer-Korvenkontio; A Vaheri
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

3.  The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations.

Authors:  Tuula K Outinen; Satu M Mäkelä; Ilpo O Ala-Houhala; Heini Sa Huhtala; Mikko Hurme; Antti S Paakkala; Ilkka H Pörsti; Jaana T Syrjänen; Jukka T Mustonen
Journal:  BMC Infect Dis       Date:  2010-05-25       Impact factor: 3.090

4.  Circulating immune complexes in patients with acute measles and rubella virus infections.

Authors:  B Ziola; G Lund; O Meurman; A Salmi
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

5.  Increased serum fibronectin levels in patients with hemorrhagic fever with renal syndrome.

Authors:  Qunying Han; Wen Kang; Lei Zhang; Sai Lou; Qianzi Zhao; Zhengwen Liu
Journal:  Inflamm Res       Date:  2009-08-22       Impact factor: 4.575

6.  Evaluation of six tests for circulating IgG complexes with special reference to IgM rheumatoid factors: analysis of systemic lupus erythematosus and rheumatoid arthritis series.

Authors:  O Wager; P Lindström; J A Räsänen; R Kekomäki; B Ziola; A Salmi; H Isomäki; B Skrifvars; K Penttinen
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

7.  Detection of specific serum immunoglobulin M in nephropathia epidemica (Scandinavian epidemic nephropathy) by a biotin-avidin-amplified immunofluorescence method.

Authors:  B Settergren; P Juto; G Wadell
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

8.  Belgrade and Hantaan hantaviruses--the causative agents of severe haemorrhagic fever with renal syndrome in children in Serbia.

Authors:  R Bogdanović; A Gligić; V Nikolić; M Ognjanović; M Marković; L Sarjanović
Journal:  Pediatr Nephrol       Date:  1994-06       Impact factor: 3.714

9.  Hantavirus regulation of type I interferon responses.

Authors:  Valery Matthys; Erich R Mackow
Journal:  Adv Virol       Date:  2012-08-08

10.  Elevated plasma soluble Sema4D/CD100 levels are associated with disease severity in patients of hemorrhagic fever with renal syndrome.

Authors:  Bei Liu; Ying Ma; Jing Yi; Zhuwei Xu; Yu Si Zhang; Chunmei Zhang; Ran Zhuang; Haitao Yu; Jiuping Wang; Angang Yang; Yun Zhang; Boquan Jin
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.